AlloSure for Heart Transplant Patients Receives CMS Draft Coverage
The
“AlloSure provides additional insights into antibody mediated rejection in heart transplant patients, an indication that is growing in our patient population,” said Dr.
“We have some strong early experience with HeartCare where clinicians are seeing the value of AlloSure and AlloMap in patient management,” said
About
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements, including statements regarding AlloSure Heart. These forward-looking statements are based upon information that is currently available to
CONTACTS:
Chief Commercial Officer
415-287-2393
sking@caredx.com
Investor Relations
Westwicke Partners
646-277-1266
david.clair@icrinc.com
Source: CareDx, Inc.